Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

İÇLİ, FİKRİ; Altundag, Kadri; AKBULUT, HAKAN; PAYDAŞ, SEMRA; BAŞARAN, Gül; Saip, Pinar; GÖKÖZ DOĞU, Gamze; Erlap, Yesim; Uslu, Ruchan; Sevinc, Alper; Onur, Handan; Mandel, Nil; Sezgin, Canfeza; Altinbas, Mustafa; Guler, Nilufer; Isikdogan, Abdurrahman; GÖKMEN, ERHAN; UYGUN, KAZIM; Ustuner, Zeki; YAREN, ARZU; Demirkan, HATİCE; Coskun, Ugur; Ata, Alper; ÖZKAN, METİN; Arican, Ali

doi:10.1007/s12282-013-0506-y

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Copy For Citation

İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., ...More

BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded)

Publication Type: Article / Article
Volume: 22 Issue: 5
Publication Date: 2015
Doi Number: 10.1007/s12282-013-0506-y
Journal Name: BREAST CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.480-485
Keywords: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
Dokuz Eylül University Affiliated: Yes

Abstract

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.